Comparison · NCT00626548-11f49c80
ZD4054 vs Placebo: Progression Free Survival
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. ZD4054 vs Placebo: Progression Free Survival. Trial comparisons, record NCT00626548-11f49c80. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00626548-11f49c80
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.221 | 0.19 | 0.256 | wilson | |
| Risk in group 2 | 0.275 | 0.241 | 0.312 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0538 | -0.103 | -0.00448 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.805 | 0.659 | 0.983 | log | |
| Odds ratio, group 1 over group 2 | 0.749 | 0.574 | 0.977 | log | |
| Number needed to treat, for one fewer participant with the outcome on ZD4054 than on Placebo | 18.6 | 9.73 | 223 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | ZD4054 | ZD4054 10 mg oral tablet once daily | 131 | 592 | OG000 |
| Group 2 | Placebo | Placebo oral tablet once daily | 162 | 589 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Progression Free Survival
- Description
Number of participants who have a progression event at the early analysis DCO, where progression is defined, using RECIST, as a measurable increase in the smallest dimension of any target or non-target lesion, or the appearance of new lesions, since baseline
- Time frame
- Participants were followed up for progression every 4 weeks for the first 16 weeks then every 16 weeks
- Population
- The analysis population only includes patients recruited by the time of the early analysis (1 October 2010)
Source ClinicalTrials.gov
Trial
- Title
- A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer
- NCT number
- NCT00626548
- Phases
- PHASE3
- Conditions
- Prostate Cancer
- Interventions
- ZD4054, Palcebo
- Lead sponsor
- AstraZeneca
- Results first posted
- 2012-06-01
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00626548?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00626548-11f49c80